Menu
Applications are now closed. Stay tuned for future opportunities!
Are you working on groundbreaking therapeutics or vaccine solutions? VITAL invites startups and university-backed projects to apply for non-dilutive funding ranging from $50K to $200K. This funding supports the development, evaluation, or validation of innovative solutions aligned with BARDA’s mission to enhance pandemic preparedness and health security.
Applications are now closed. Follow VITAL on LinkedIn to stay informed about future opportunities!
Startups and projects will receive project management support and regular mentoring from subject matter experts over the award duration (6 months).
Demonstrate proof-of-concept for high risk, breakthrough technologies and platforms
Advance technologies currently in development to the next milestones and value inflection points
Submit your application before August 23 to enter to be selected for the milestone-based awards.
We will notify you by September 30 whether you have been selected to receive non-dilutive funding and project management support.
Starting mid-October, you will receive regular mentoring from subject matter experts to help advance your innovation.
Watch our info session to gain insights into the VITAL Biotech Accelerator Program and Funding opportunities.
Innovative vaccine and therapeutic technologies and platforms aligned with BARDA’s mission.
For more information on BARDA areas of interest, visit https://drive.hhs.gov/partner.html.
BARDA also recently released TPPs relevant to some of its areas of interest: https://medicalcountermeasures.gov/barda/tpp.
We are accepting applications from academic projects and innovators, as well as early-stage biotech companies globally, targeting the U.S., Europe, and Asia.
We are accepting applications from academic projects and innovators, as well as early-stage biotech companies globally, targeting the U.S., Europe, and Asia. Companies and individuals are welcome to apply for both the Accelerator Program and non-dilutive funding from VITAL. Applications will be reviewed independently. Solicitations for both the Accelerator Program and non-dilutive funding opportunities will be open on an annual basis.
Applications will be reviewed wholistically and comprehensively based on responses to the questions in the application, with particular attention being given to the amount of funds requested, the milestones to be achieved with those funds, the timing of the milestones, the specific use of funds, and the resource plan to achieve the milestones.
Company or Individual Affiliations: Applications from companies or individual innovators from universities in the following countries will be subject to additional review: Afghanistan, Balkan countries, Burma, Central African Republic, Congo, Crimea and covered regions of Ukraine, Cuba, Ethiopia, Hong Kong, Iran, Iraq, Lebanon, Libya, Mali, Nicaragua, North Korea, Russia, Russian occupied Ukraine, Sudan, Syria, Venezuela, Yemen, and Zimbabwe.
Non-dilutive funds will be awarded in U.S. dollars.
Rights to intellectual property developed using non-dilutive funds from BARDA VITAL remain with the company. As with all non-dilutive funds awarded by the U.S. government, including funds awarded by the U.S. National Institutes of Health (NIH), the U.S. Government can exercise “walk in rights” to develop intellectual property it deems valuable, if that intellectual property is not being developed by the company. VITAL has no knowledge of any instances when the U.S. Government has ever exercised its walk-in right, including during the Covid-19 pandemic.
There will be reporting requirements on a quarterly basis, based on milestones achievement, and a final report.
Companies and individuals that receive funding from VITAL will have access to BARDA subject matter experts and other related BARDA resources. Access to these BARDA resources will be managed and coordinated by the VITAL Lead Mentor.